SkinMedica and New York University Enter Into License Agreement for Novel Skin
Lightening Program
SAN DIEGO and NEW YORK, Oct. 26 /PRNewswire/ -- SkinMedica, Inc. and New York
University announced today that they have entered into a global license
agreement to develop novel products to address skin hyperpigmentation based on
technology invented at NYU.
"Our scientific discovery involves natural products that act by an entirely
novel mechanism to modulate skin pigmentation," said Seth J. Orlow, M.D.,
Ph.D., Chair of the Ronald O. Perelman Department of Dermatology at NYU, and
Director of the Program in Cutaneous Biology and NYU Langone Medical Center's
Center of Excellence in Cancers of the Skin. "The treatment of
hyperpigmentation remains a major unmet need, and we are especially pleased to
partner with SkinMedica to advance new products to address this problem."
Under the terms of the agreement, SkinMedica has licensed exclusive rights to
develop and market products based on the NYU technology, with a range of
applications in the modulation of skin pigmentation.
"Dr. Orlow has a long history of innovation and invention in dermatology and
skin biology, and we are proud to partner with him and NYU to deliver novel
products for pigmentation," said Mary Fisher, SkinMedica President and CEO.
"Hyperpigmentation is a very common problem worldwide, with limited treatment
options. We look forward to advancing this program, which has enormous global
market potential."
About Hyperpigmentation
Hyperpigmentation is a common condition in which patches of skin become darker
in color than the surrounding skin. It can affect the skin color of people of
any race. Normal skin color is formed by melanin, which is produced by
special cells called melanocytes in the top layer of the skin. Uneven melanin
production can occur in response to hormonal changes, and may also occur with
certain diseases. Another common presentation is in response to skin damage
or inflammation. It is advisable for persons with pigmentary problems to
visit a dermatologist for a discussion of diagnosis and treatment options, and
to rule out skin cancer.
About NYU Langone Medical Center's Ronald O. Perelman Department of
Dermatology
The Ronald O. Perelman Department of Dermatology of the New York University
School of Medicine traces its history back 127 years to the founding of the
New York Skin & Cancer Hospital in 1872. The Department's faculty members
deliver state-of-the-art medical, surgical and cosmetic dermatologic care at
over 100,000 visits annually at NYU Langone Medical Center and its affiliated
medical centers. In addition, the Department is one of the leading research
centers for investigations into the basic biology of the skin and hair as well
as the diagnosis and management of dermatologic diseases.
About SkinMedica
SkinMedica, Inc. is focused on developing, acquiring and commercializing
products that treat dermatologic conditions and improve the appearance of
skin. We market and sell to physicians, with a focus on aesthetics, both
prescription and non-prescription skin care products.
The company's full line of aesthetic skin care products includes the
revolutionary TNS Essential Serum(TM) and hallmark TNS Recovery Complex®. The
formulations in our clinical skin care collection enhance skin appearance,
reduce signs of aging and provide other skin care benefits.
SkinMedica's prescription products include VANIQA® (eflornithine
hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for
the reduction of unwanted facial hair in women and EpiQuin® Micro Cream (4%
hydroquinone) for hyperpigmentation, or "brown spots" that commonly result
from aging, inflammation or sun exposure.
SkinMedica is based in Carlsbad, California.
TNS Recovery Complex®, VANIQA®, EpiQuin® Micro, and SkinMedica®, are
registered trademarks of SkinMedica, Inc and affiliates.
For more information, visit www.skinmedica.com.
SOURCE SkinMedica, Inc.
Adrienne Bavar or Stephanie Boccuzza at ShopPR, +1-212-829-1111
